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Summary
The scope of the thesis was to íurther develop assays oí serotonin, catecholamines
and their metabolites, and to investigate their usefulness in diagnosis and follow-up
oí patients with carcinoid tumours, further elucidation of catecholamine metabo-
lism, and experimental therapies of Parkinson's disease.
The introduction (Chapter 1) describes biochemical, (patho)physiological and
analytical aspects of serotonin and catecholamines. Serotonin and catecholamines
are low molecular weight biogenic amines, that are present throughout the human
body in specialised neurones, organs and certain cell types. By their interaction
with specific cell membrane receptors as both neurotransmitters and hormones
they are intricately involved in a wide variety of (patho)physiological processes in
the central nervous system and periphery. Serotonin is a prominent indolamine in
enterochromaffin cells of the gastrointestinal trac! platelets and serotonergic neu-
rones of the brain. lt is implicated in processes uch as smooth muscle contraction,
vasoconstriction and both peripheral and central nervous system neurotransmis-
sion. The quantitatively most pronounced aberration in serotonin production and
metabolism is encountered in patients with carcinoid tumours.
The catecholamines dopamine (DA),  noradrenal ine (NA) and adrenal ine (A)  are
monoamines with distinct biological actions. They are diííerently distributed among
cells located in brain, peripheral sympathetic nervous system and chromaffin tissue
in the adrenal medulla. Generally, catecholamines function as neurotransmitters in
the central nervous system and as both neurotransmitters and hormones in the pe-
riphery. Catecholamines are involved in the control oí cardiac output and distribu-
tion of blood ílow, whereas their visceral effects in organs other than the cardio-
vascular system direct vegetative functions (e.g. smooth muscle function, f luid and
electrolyte transpor! cell growth and haemostasis). Metabolic effects include regu-
lation of oxygen uptake and mobil isation of energy from storage depots. Catechol-
amine (metabolite) producing tumours such as phaeochromocytoma nd neuro-
blastoma, and neurodegenerative diseases uch as Parkinson's disease are among
the wide variety of diseases in which catecholamines play important roles.
Chapter 2 deals with several clinical chemical aspects of carcinoid tumours. These
are APUD-omas (tumours characterised by amine precursor uptake and
decarboxylation) that arise from enterochromaffin cells of the gastrointestinal tract
and characteristically synthesise and secrete serotonin. According to the site of
origination they can be classified into carcinoids from foregut (respiratory tract,
pancreas,  s tomach and duodenum),  midgut  ( i leum and appendix) ,  and h indgut  ( le í t
colon and rectum). Dependent on site oí origination and mass, carcinoids are
known to give rise to excessive synthesis, storage and release of serotonin, its
precursor 5-hydroxytryptophan (S-HTP), and its major metabolite 5-hydroxyindole-
3-acetic acid (5-HIAA). The endocrine manifestation of carcinoid tumours, which is
referred to as the carcinoid syndrome, comprises ílushing, diarrhoea, valvular heart
disease and asthma-like symptoms. The tumours appear most frequently in midgut
and to a lesser extent in fore- and hindgut. Depending on origin and size of the
primary tumour, distant metastases (usually to l iver) can occur.
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Chapter  2.1 descr ibes a high per formance l iqu id chromatographic (HPLC) method
with quaternary gradient elution and fluorometric detection that enables qualitative
or quantitative profi l ing of tryptophan (TRP), 5-HTP, serotonin and 5-HIAA in urine,
p late let  r ich p lasma and ( tumour)  t issue of  pat ients wi th carc inoid tumours.  Pr ior  to
in ject ion ur ines were d i lu ted and f i l tered.  Plate let  r ich p lasma and t issue homoge-
nates were prepurif ied by C,u solid phase extraction. The detection l imits were ap-
proximately 2 pmol. Mean within and between series recoveries íor diluted urines
ranged írom 92.6-114.4o/" and 84.3-111.87o, respectively. Results of simultaneous
assays of urinary serotonin and 5-HIAA compared favourably with those of single
component  analyses by s imi lar  HPLC methods.  C16 extract ion of  indoles í rom pro-
tein containing matrices was studied in platelet rich plasma. Recoveries of added
standards were not íully satisÍactory as yet. Examples oÍ indole profi les prepared
from urine, platelet rich plasma and tissue oÍ healthy persons and patients with
carc inoid tumours are g iven.  Using the newly developed method we invest igated
diurnal variation of urinary TRP, serotonin, and 5-HlAA, together with the influence
oÍ  a serotonin poor  d iet .  No consistent  d iurnal  var iat ions were Íound in ' l  2  h ur ine
samples f rom 15 heal thy adul ts .  Abst inence of  serotonin r ich foods reduced ur inary
serotonin and 5-HIAA levels.  Al though t ime consuming and compl icated for  dai ly
routine usage the present approach oífers particular advantages over single com-
ponent analyses in the study oí TRP metabolism in patients with carcinoid tumours.
Reduct ion oí  p lasma TRP pool  (caused by long term augmentat ion of  serotonin
biosynthetic pathway), metabolic shifts (e.g. shift írom 5-HIAA production to its al-
coholic counterpart S-hydroxytryptophol due to impaired hepatic functioning),
production of unusual metabolites (such as tentatively identií ied N-acetyl-serotonin
dur ing carc inoid cr is is)  and metabol ic  contr ibut ions of  normal  organs (e.g.  conver-
s ion of  secreted tumour 5-HTP to serotonin in  k idneys and other  organs)  can s imul-
taneously be studied.
Chapter 2.2 describes the influence of certain foods on commonly used clinical
chemical  markers for  neuroendocr ine tumours.  The c l in ica l  chemical  d iagnosis and
fo l low-up of  b iogenic amine producing neuroendocr ine tumours,  notably phaeo-
chromocytoma, neuroblastoma and carcinoid tumours, is usually performed by
quantitative analysis of their urinary metabolites. Certain foods contain substantial
quant i t ies of  b iogenic amines.  Especia l ly  f ru i ts  l ike banana,  p ineapple and k iwi  hold
high concentrat ions of  DA, serotonin and to a lesser  extent  NA. Ingest ion of  these
foods causes increased ur inary excret ion of  b iogenic amine metabol i tes,  and
thereby hampers c l in ica l  chemical  d iagnosis of  b iogenic amine (metabol i te)  secre-
t ing tumours.  Using h igh per formance l iqu id chromatography and gas chromato-
graphy we reevaluated the influence of a serotonin and DA rich diet on platelet
serotonin and serotonin,  5-HIAA and major  catecholamine metabol i tes
(homovanil l ic acid, HVA; 3,4-dihydroxyphenylacetic acid, DOPAC; vanil lylmandelic
acid, VMA; 3-methoxy-4-hydroxyphenylethylene glycol, MHPC) in the urine of ' l  5
healthy adults. The study was preceded by an overnight Íast. During the 24 h ex-
periment two test meals, composed of banana, walnut, pineapple and kiwi, were
consumed. Between and after test meals all drank pineapple juice. The estimated
total intakes of 5-HTP, serotonin, 5-HlAA, DA and NA were: 2.7, 266, 2.4, 35.0 and
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one would derive írom a normal Western diet. Timed urine and blood samoles
were collected before, during and aíter the test meals. Although there were signifi-
cant responses in urinary free serotonin and catecholamine metabolites (HVA,
DOPAC and VMA; not MHPC), their levels did not exceed the upper l imits of the
reference ranges íor any of the participants. The diet iníluenced both free and total
(sum oí free and conjugated) urinary serotonin. For urinary 5-HIAA pronounced
effects were already observed within 2-4 h following the first test meal. After 6-8 h
urinary 5-HIAA of 1 1 participants (73o/o) exceeded the upper l imit of the reíerence
range. At that t ime the median peak urinary 5-HIAA concentration was 40 (range:
5-1 57) times higher than the median basal concentration. The median recovery of
dietary serotonin as urinary 5-HlAA, as calculated from the areas under the 5-HIAA
curves and estimated serotonin intake, was 20"/o and subject to a large range (1-
50%). Dietary 5-HTP may have contributed to urinary excretion of serotonin and 5-
HIAA. There was no significant change in platelet serotonin. lt is concluded that,
using specific analytical methods, no dietary restrictions have to be imposed for di-
agnosis of catecholamine (metabolite) producing tumours. There are considerable
interindividual responses with regard to uptake, metabolism or excretory route of
dietary serotonin. In case of diagnosis oí carcinoids on the basis oí urinary 5-HIAA
it is appropriate to adhere to complete abstinence of serotonin containing foods
for at least 12 h. Short term intakes of dietary I-HIP (2.7 pmol) and serotonin (266
pmol) do not inÍluence platelet serotonin contents and have minor effects on uri-
nary free serotonin.
The usefulness of serotonin and its metabolites íor the diagnosis oí carcinoid pa-
tients is described in chapter 2.3. Carcinoid patients are usually diagnosed bio-
chemically on the basis of increased urinary excretion of 5-H|AA. Probably de-
pendent on distribution between fore, mid- and hindgut carcinoids, the diagnostic
sensitivity of urinary 5-HIAA is reportedly 18-88%. Urinary and platelet serotonin
concentrations are considered to provide complementary information. Using es-
tablished high performance liquid chromatography methods with fluorometric de-
tection, we evaluated the clinical usefulness oí measurements oí urinary S-H|AA,
and urinary, plasma and platelet serotonin in 30 consecutive patients (.1 3 fe-
males/1 7 males, median age 59.5 years) with histologically proven carcinoid tu-
mours of  fore-  (n= ' l  1) ,  mid-  (n=1a) and h indgut  (n:5)  or ig in before t reatment .  ln
addition, serotonin contents oÍ 7 primary tumours and 4 metastases (3 l iver, 1 skin)
were studied. Reference values [median (95% non parametric confidence interval)]
for 26 healthy adults were: urinary 5-HlAA, 1.6 (0.8-3.8) mmol/mol creatinine; uri-
naÍy serotonin, 36 (25-66) ;.rmol/mol creatinine; platelet serotonin, 4.4 (2.9-5.4)
nmol/10e platelets; and plasma serotonin, not detectable (<0.5-33.3) nmol/|. Ten
patients showed no signs of serotonin overproduction and 14 had both increased
urinary 5-HIAA and platelet serotonin. Platelet serotonin, but not urinary 5-HlAA,
was increased in 6. None of them had increased urinary 5-HIAA excretion without
an increase in platelet serotonin content. Platelet serotonin (urinary 5-HIAA)
[urinary serotonin] were increased in 5/1 1 (1 111) 12l7l patients with foregut-,
14/14 (13114) [10/13]  wi th midgut  and 1/5 (Ols)  [2 /51wi th h indsut  carc inoid
tumours.  Pr imary tumour serotonin contents ranged f rom 0.01 1-12,5OO nmol /g
wet tissue; those of metastases from 0.006-36,400. Primary foregut- and hindgut-
had lower tumour serotonin contents than primary midgut carcinoids. Long-term
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monitoring of three patients showed that tumour (re)growth caused platelet
serotonin to exceed the upper l imi t  o f  the reíerence range at  an ear l ier  s tage than
urinary 5-HlAA. Determination of plasma serotonir.r in carcinoid patients showed
that  increasing p late let  serotonin was accompanied by increasing p lasma
serotonin. Since platelet serotonin was calculated by taking the ratio of the
concentrations of serotonin and platelets in platelet rich plasma, it would be
appropr iate to refer  to 'apparent 'p late let  serotonin content .  In  cases wi th h igh
rates of tumour serotonin secretion, platelet serotonin reached a maximum (at
about 45 nmol/10e platelets) and did not correlate with serotonin secretion rate,
whereas urinary 5-HIAA was correlated. Carcinoid serotonin secretion rate can
apparently exceed the maximum uptake capacity of the total body platelet pool.
Increased p late let  serotonin was corre lated wi th increased p lasma serotonin and
wi th occurrence of  carc inoid syndrome. Increased ur inary serotonin,  a l legedly
caused by increased c i rcu lat ing levels of  S-HTP, a lmost  invar iably  coinc ided wi th
increased p late let  serotonin,  but  not  necessar i ly  wi th above-normal  ur inary 5-HIAA
excret ion.  From these resul ts  and long- term moni tor ing of  three pat ients dur ing
treatment, we conclude that platelet serotonin is more sensitive than urinary 5-
HIAA for  detect ing carc inoids that  secrete only  smal l  amounts of  serotonin.  This
especially improves clinical chemical diagnosis of patients with foregut carcinoids,
who harbour tumours that  secrete only  smal l  amounts of  serotonin.
Because of  thei r  presumed embryonic or ig in f rom neuronal  ectoderm and thei r
abil ity to take up and decarboxylate amine precursors, intestinal carcinoids are re-
ferred to as "gut  APUDomas."  On the basis  of  the coní inement  of  carc inoid tu-
mours to the APUD system, addi t ional  product ion of  catecholamines and
histamine is  conceivable.  Chapter  2.4 descr ibes a study in  which we moni tored
long- term (median 1 1 months,  maximum f ive years)  p late let  serotonin and ur inary
serotonin, 5-HIAA and 7 catecholamine metabolites in 44 patients (24 females, 20
males,  median age 62 years,  range 13 88)  wi th h is to logical ly  proven carc inoid
tumours oí  Íore-  (n=1a),  mid (n:25)  and h indgut  (n:5)  or ig in.  In  addi t ion,  tumour
serotonin and catecholamine contents (11 pat ients)  and ur inarv h is tamine and N-
methylh is tamine (15 pat ients)  were determined.  There were s igni í icant  d i f íerences
in platelet serotonin contents between the three subgroups, with highest values in
pat ients wi th midgut  carc inoids and lowest  in  those wi th h indgut  carc inoids.
Ur inary 5-HIAA oí  pat ients wi th midgut  carc inoids was s igni f icant ly  h igher  than that
of  pat ients wi th fore-  and h indgut  carc inoids.  Ur inary serotonin excret ion levels
were highest in midgut carcinoid patients, and differed significantly between íore-
and midgut  carc inoid pat ients.  Al though median levels and upper l imi ts  oÍ  ur inary
DA-metabolite excretion levels were highest in midgut carcinoid patients, no
sigrrif icant differences were found between the three subgroups. Subgroup
differences between urinary excretion levels of NA and A metabolites were not
significant either. Consistently increased levels of indoles, notably platelet
serotonin, were observed in 96, 43, and O"Á of patients with mid-, fore- and
hindgut carcinoids, respectively. Urinary DA metabolites, notably 3-
methoxytyramine, were consistently increased in 38, 20 and 7"/" of patients with
mid-, hind- and foregut, respectively. For urinary NA/A metabolites, notably
normetanephrine and metanephrine, these data were 33, 20 and 14"/", re-
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serotonin, not detectable-52,66o pmol DA, 40-1 5,000 pmol NA and not detect-
able-1,690 pmol A. Midgut carcinoid tumours had highest serotonin contents,
whereas those oí catecholamines were independent from primary localisation.
There was no consistent relation between tumour biogenic amine contents and
urinary metabolite excretion. occurrence of carcinoid syndrome related to in-
creased serotonin production rate. Increased histamine production is not an impor-
tant feature in patients with lung carcinoids or l iver-metastasised ileum carcinoids.
I t  is  unclear  whether  catecholamines in carc inoid tumours or ig inate f rom (par t ia l )
de novo synthesis, uptake, or combinations. Massive release of catecholamines
from carcinoid tumours may be involved in init iation of í lushing.
Chapter 2.5 reviews several biochemical aspects of carcinoid tumours and current
strategies in the treatment oí patients harbouring these tumours. The correct diag-
nosis of carcinoid tumours is sometimes diff icult. They are to be distinguished írom
adenocarc inomas and other  neuroendocr ine tumours.  Histo logical  examinat ion
provides the ultimate prooí for their presence. Urinary 5-HIAA excretion is usually
determined for the biochemical diagnosis of carcinoid tumours. lts levels can, how-
ever, be influenced by consumption of serotonin-rich food. On the other hand,
platelet serotonin is unaÍfected by Íood intake and more sensitive íor the diagnosis
of carcinoids that secrete only small amounts of serotonin. ln addition to serotonin,
carcinoid tumours may secÍete several other biogenic amines and peptides. Their
measurements may assist in biochemical diagnosis. Therapy of metastasised carci-
noids is directed at tumour andf or symptom reduction. Tumour reduction can be
achieved by surg ical  debulk ing or  by embol isat ion.  Combinat ion chemotherapy
has maximum response percentages oí about 337o. Over the last years the
synthetic somatostatin analogue octreotide and interferon alpha have been
investigated for their useÍulness in carcinoid patients. Therapy with these
substances rarely results in reduction of tumour size (1O-2O%), but causes
symptom reduction in most patients. Increasing knowledge of the various
serotonin receptors and their antagonists may lead to development oí new
treatment strategies for patients with metastasised carcinoid tumours. lt may be
expected that different treatment modalit ies wil l increasingly be combined in the
future.
Chapter 3 describes an improved method for the quantif ication oí 3-O-methylated
catecholamine metabol i tes in  ur ine (chapter  3.1)and a study on per inata l  organ
content and age-dependent urinary concentrations of N-methyladrenaline (N MA)
(chapter 3.2). Contributions to experimental therapies in Parkinson's disease were
made by studying the metabolism of the synthetic NA precursor L-threo-3,4-dihy-
droxyphenylserine in rats (chapter 3.3) and by investigating the possibil i ty to char-
acterise fetal ventral mesencephalon by the measurement of its catecholamine
content (chapter 3.4).
In chapter 3.1 we describe the development oí a method for simultaneous quanti-
f ication oÍ the urinary 3-O-methylated catecholamine metabolites 3-
methoxytyramine, normetanephrine and metanephrine by stable isotope-dilution
ammonia chemical ionisation mass fragmentography. Clinical chemical laboratories
notably quantify catecholamines and their metabolites for the diagnosis and follow-
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up of catecholamine (metabolite) producing tumours. Determination of urinary to-
ta l  metanephr ines i  general ly  considered to be the pr inc ipal  test  for  the c l in ica l
chemical  d iagnosis of  phaeochromocytoma. These are NA and/or  A producing tu-
mours that notably derive from the adrenal medulla in adults. Several analytical
techniques for  the analyses oí  ur inary metanephr ines have been developed.  Analy-
sis by stable isotope-dilution mass fragmentography provides a potential combina-
tion of high sensitivity, selectivity, precision and accuracy. Simultaneous deconju-
gation and pentafluoropropionylation of metanephrines was performed by heating
residues of  lyophi l ised ur ines (300 p l )  íor  15 min at  BO"C in a mixture of  d imethyl -
formamide, acetonitri l  and pentafluoropropionic anhydride. The reaction was fol-
lowed by extraction in a water/heptane mixture, evaporation of the heptane layer
and rederivatisation of the residue in a mixture of ethyl acetate and pentaÍluoro-
propionic anhydride at room temperature. Detection l imits for 3-methoxytyramine,
normetanephr ine and metanephr ine were 0.3,  2.6 and 0.3 pmol  on column, re-
spectively. Twenty-íour urinary excretion levels of nineteen apparently healthy
adults (ages 27-63 years) were established. Median (nonparametric 95'% confi-
dence intervals) levels, expressed in pmol/mol creatinine, were: 3-methoxytyramine
86 (58-139),  normetanephr ine 141 (82-234) and metanephr ine 66 (38-87) .  Com-
pared wi th our  prev iously  descr ibed method,  based on ac id hydrolys is ,  a lka l ine ex-
traction, derivatisation and electron-impact mass fragmentography, the present
method was found to be less laborious, more sensitive and presumably more accu-
rate. The employed prepurif ication method may prove applicable for proÍi l ing of a
variety of naturally occurring mono-, di-, and polyamines in biological samples.
Chapter 3.2 describes age-dependent urinary excretion and perinatal organ con-
tents of N-methyladrenaline in relation with those of DA, NA and A. N-methy-
ladrenaline is formed by N-methylation oí A, catalysed bry phenylethanolamine-N-
methyltransferase. Early pharmacological experiments revealed that N-methyl-
adrenal ine xhib i ts  propert ies that  are at  best  descr ibed as a mixture oí  those of
DA, NA and A. These effects, e.g. increases of blood glucose and diastolic and sys-
to l ic  b lood pressures and decrease oí  pulse rate,  were observed at  10-40 t imes
higher doses than A and NA, and at comparable DA dose. N-methyladenaline f-
fects on systolic blood pressure lasted longer than those of A. Since its f irst demon-
strat ion,  the number of  c l in ica l  chemical  s tudies on N-methyladrenal ine has been
scanty.  Using h igh per formance l iqu id chromatography wi th e lect rochemical  de-
tect ion we determined f ree DA, NA, A and N-methyladrenal ine in : 1)  ur ines f rom
newborns,  ch i ldren and adul ts ,  and 2)  adrenals,  organ of  Zuckerkandl ,  dorsal  roots
and perirenal brown adipose tissue from deceased fetuses, very premature and
term newborns and infants. Data írom children and adults showed that contribu-
t ions oí  A and N-methyladrenal ine to the sum oÍ  ur inary f ree catecholamines in-
crease with age. Relative amounts of A and N-methyladrenaline increased in both
adrenal and extra adrenal chromaffin tissues from late gestation up to several
months of postnatal l i fe. Increase of adrenal N-methyladrenaline content follows
endocr ine maturat ion of  the medul la ,  phenylethanolamine-N-methyl t ransferase in-
duction and subsequent A synthesis. Relative amounts of N-methyladrenaline in ex-
tra adrenal chromafíin tissue increase in a period that is associated with the regres-
s ion of  th is  t issue.  l t  is  as yet  unclear  wether  N-methyladrenal ine íunct ions as e i ther
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ln Chapter 3.3 we investigated the metabolism oí L-threo-3,4-dihydroxyphenyl-
serine (L-DOPS). L-DOPS is a synthetic NA precursor that is currently evaluated for
its applicabil ity in patients with Parkinson's disease. Degeneration of DA containing
neurones is  the main defect  in  Park inson's  d isease.  Addi t ional  decreases oí  NA
contents in several brain areas have been reported. To increase central DA levels
oral therapy with L-3,4-dihydroxyphenylalanine (L-DOPA) and a peripheral
decarboxylase inhibitor is widely used. Additional treatment with L-DOPS was
suggested to increase central NA levels and thereby ameliorate the freezing
phenomenon, all day l ife activity and mood. We compared the metabolic íate oí
orally administered L-DOPS with that of L-DOPA in rats. Administration of 431162
mmol L-DOPS/kg, day via the drinking water showed that, in contrast to
conversion of L-DOPA to DA and metabolites (15.5 molTu oÍ ingested dose), L-
DOPS is  only  to a minor  extent  (1.0 mol%) decarboxylated to NA and metabol i tes.
The major urinary excretory forms were DOPS (6.9 mol%) and 3-O-methyl-DOPS
(6.4 mol%). The major part of urinary NA (0.7 mol%) may derive from
decarboxylation of L-DOPS by renal aromatic L-amino acid decarboxylase. Urinary
normetanephrine amounted to 0.2 molTo and may derive from the action oí
catechol-O-methyltransÍerase on circulating NA. The monoamine oxidase products
vanil lylmandelic acid and 3-methoxy-4-hydroxyphenylethyleneglycol were
estimated to amount to 0.1 mol%, or less. L-DOPS decarboxylation is strongly
inhib i ted by coadminis t rat ion of the per ipheral  decarboxylase inhib i tor  carb idopa
at a clinically used dose. In contrast with the firrdings with L-DOPA, carbidopa did
not increase the bioavailabil ity of oral L-DOPS. Coadministration of an equal dose
of D-DOPS inhibited L-DOPS decarboxylation by about 417o, whereas L-DOPA
coadministration had no effect. Conversely, L-DOPS did not afíect L-DOPA
metabolism, even not when it was combrined with carbidopa. lt is concluded that
there are major differences between the metabolism of the natural and synthetic
catecholamine precursors L DOPA and L-DOPS. These are largely caused by
differences in decarboxylation rates. The present data are in l ine with previous
observat ions regarding the metabol ism of  DL-DOPS in Park insonian pat ients
treated with L-DOPA, carbidopa and DL-DOPS. The biochemical brasis of the
reported beneíicial effects oí L-DOPS in patients with Parkinson's disease is as yet
unclear .
Stereotact ic  implantat ion of  human dopaminergic  ventra l  mesencephalon (VM)
grafts is a rapidly developing treatment modality in Parkinson's disease. For this,
implantation of fetal dopaminergic tissue into neurotoxin-denervated host rats fre-
quently serves as an animal model. Careíul excision of VM tissue of the proper ges-
tational age contributes to successíul grafting. In chapter 3.4 we investigated the
possibil i ty to characterise rat fetal VM tissue on the basis of its catecholamine con-
tents. For this we determined DA, NA and A, and immunohistochemically stained
tyrosine hydroxylase (TH) and DA in dissected rat VM tissue írom embryonic day
(ED) 14 to postnata l  day (P)  1 7.  Whole VM t issue DA, NA and A contents in-
creased wi th advancing age.  VM DA/prote in increased f rom ED14 to ED16,
whereas NA/orote in increased f rom ED15 to ED 16 and f rom ED20 to P4.  VM
1 7 3
DA/NA rat io  increased f rom ED14 to ED15 and decreased í rom EDlB to P4.  VM
cell suspensions exhibited higher DA/NA ratios than whole VM tissue. Washed cell
suspensions had higher DA/NA than their unwashed counterparts. From these and
immunochemical data we concluded that results from both VM immunohistochem-
istry and catecholamine assays relate to VM development. VM DA is mainly con-
tained in cells, whereas VM NA is located in fibres that channel at the dorsal side
of the VM. ldentif ication by catecholamine analysis may especially be of
importance for the characterisation of the VM in suction aborted human fetal
t issues. lf possible, symmetrical cleavage and usage oí both parts for biochemical
characterisation and implantation, respectively, may be the most adequate
approach.
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